Design and Development of Novel, Highly-Selective HDAC6 Inhibitors for the Treatment of Cancer

Design and Development of Novel, Highly-Selective HDAC6 Inhibitors for the Treatment of Cancer. Cecil A., Rogers H., Bone E., Colman L., Finan P., Haque K., Lensun L., Roitt R., Silva F., Ward P., Whale A., Shuttleworth S. NCRI Meeting, Liverpool, UK, November 3, 2014, A114.

Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/δ Inhibitors for the Treatment of Cancer (NCRI Meeting)

Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/d Inhibitors for the Treatment of Cancer. Cecil A., Rogers H., Bone E., Colman L., Finan P., Haque K., Lensun L., Roitt S., Silva F., Ward P., Whale A. Shuttleworth S. NCRI Meeting, Liverpool, UK, November 3, 2014, A143.